evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract
19252,GENE_BACKGROUND,,"The HLA-A (Human Leukocyte Antigen A) gene encodes for the heavy chain subunit of the Major Histocompatibility Complex class I (MHC I) complex. A critical component of the immune system is the presentation of foreign antigens on the cell surface by the MHC molecules (PMID: 10974135). Tumor cells are vulnerable to such an immune response due to the presentation of tumor-specific antigens such as mutated oncoproteins on the cell surface (PMID: 24782321, 24244023, 23157435). Several types of tumors are known to evade such an immunological response by crippling the levels of MHC I-presenting antigens on tumor cell surfaces (PMID: 24782321, 24244023, 23157435, 11665717). The HLA-A genes encode for the heavy chain subunit of the MHC (PMID: 22434516). In many tumors a reduction in HLA-A levels is seen which may be due to factors like genomic alteration, transcriptional regulation, protein transportation, and oncogene regulation (PMID: 24244023, 11665717). Genomic alterations are observed only rarely: e.g. chromosomal loss resulting in loss of the HLA locus is observed in 13.8% of colon tumors, 17.6% of laryngeal tumors, 15.3% of melanoma tumors and 17.2% of epithelial squamous cell carcinomas (PMID: 9057360). In HCT116 colorectal cancer cells HLA-A1 and HLA-A2 are down regulated by DNA methylation and by the action of the MEK pathway (PMID: 19569244). Similarly, gastric and esophageal cancers also display HLA-A downregulation via action of RAS, MYC and the HER2 oncogene, as well as the MAP kinase signal transduction pathway (PMID: 24244023, 20715101, 20628381). A major implication from a therapeutic standpoint is to target immunotherapy at patients whose cancers display an evasion of the immune system via HLA-A reduction (PMID: 9057360, 24782321, 23157435).",,2017-04-06,,3105,HLA-A,"major histocompatibility complex, class I, A",False,ENST00000376809,NM_001242758.1,HLAA,HLA-A11,HLA-A33,Aw-33,Aw-74,True,24244023,The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.,"Journal of immunology (Baltimore, Md. : 1950)",2017-12-15T20:13:00,191,12,6261-72,Mimura K et al,doi: 10.4049/jimmunol.1301597,,2017-12-15T19:50:00,,20715101,T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.,International journal of cancer,2018-01-15T20:11:00,128,2,390-401,Mimura K et al,doi: 10.1002/ijc.25613,,2018-01-15T04:01:00,,23157435,Immunogenic cell death in cancer therapy.,Annual review of immunology,2013,31,,51-72,Kroemer G et al,doi: 10.1146/annurev-immunol-032712-100008,,Kroemer G et al. Annual review of immunology. 2013;31()51-72.,,20628381,Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.,British journal of cancer,2018-08-10T20:10:00,103,4,552-9,Maruyama T et al,doi: 10.1038/sj.bjc.6605772,,0001-08-10,,19569244,Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.,International journal of cancer,2018-10-01T20:09:00,125,7,1626-39,Sers C et al,doi: 10.1002/ijc.24557,,0001-10-01,,10974135,The HLA system. First of two parts.,The New England journal of medicine,2018-09-07T20:00:00,343,10,702-9,Klein J et al,,,0001-09-07,,9057360,Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.,0001-01-01,0001-02-01,18,2,89-95,Garrido F et al,,,0001-02-01,,24782321,Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.,Genome research,2018-05-01T20:14:00,24,5,743-50,Brown SD et al,doi: 10.1101/gr.165985.113,,0001-05-01,,11665717,MHC antigens and tumor escape from immune surveillance.,Advances in cancer research,2001,83,,117-58,Garrido F et al,,,Garrido F et al. Advances in cancer research. 2001;83()117-58.,,22434516,Structural and functional distinctiveness of HLA-A2 allelic variants.,Immunologic research,2018-09-01T20:12:00,53,2001-01-03,182-90,Chen KY et al,doi: 10.1007/s12026-012-8295-5,,2002-01-03,
19251,GENE_SUMMARY,,HLA-A encodes for the heavy chain subunit of the Major Histocompatibility Complex class I (MHC I) complex. Human tumors can evade recognition by the immune system by reducing levels of MHC I presenting antigen on the cell surface.,,2017-04-06,,3105,HLA-A,"major histocompatibility complex, class I, A",False,ENST00000376809,NM_001242758.1,HLAA,HLA-A11,HLA-A33,Aw-33,Aw-74,True,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
